First Of Its Kind: New Condom May Kill HIV And HPV
Originally printed 7/23/2014 (Issue 2229 - Between The Lines News)
AUSTRALIA - A pharmaceutical company out of Melbourne has designed a gel, much like spermicide, that has been found to be 99.9 percent effective at deactivating HIV, herpes, bacterial vaginosis and HPV. This gel will soon be added to Australian condoms, available for purchase throughout the country.
VivaGel is the brainchild of Starpharma, an Australian Biotech firm. The active ingredient is astodrimer sodium, designed specifically with HIV and HSV antiviral activity and human safety in mind. The designed condom contains .5 percent of the non-antibiotic, antimicrobial drug.
It was released on July 21, at the 20th International AIDS Conference, that Australia's Therapeutic Goods Administration, much like the U.S. FDA, has approved the use of VivaGel condoms. This paves the way for them to go on sale within months in a new line of Ansell condoms, the makers of Lifestyles, in the down under country.
"With the launch of LifeStyles Dual Protect expected in the near future, certification by TGA marks another major milestone for the VivaGel condom and our partnership with Ansell, one of the world's leading condom companies and healthcare innovators," Starpharma Chief Executive Officer, Dr Jackie Fairley said.
The global branded condom market is estimated to be worth approximately $1.1 billion. Ansel's share of the condom market is round 70 percent, according to businesswire.com.
"Our partnership with Starpharma is a great example of two highly innovative Australian businesses working together to bring to market a ground-breaking new sexual health product. New product development is central to Ansell's business strategy and this highly innovative product is exciting for both companies," Ansell President & General Manager, Sexual Wellness Global Business Unit, Peter Carroll, said.
In the United States, VivaGel was granted Special Protocol Assessment agreement on July 14 from the FDA on the design and planned analyses of the phase 3 clinical studies of the VivaGel bacterial vaginosis (BV) product for the prevention of recurrent bacterial vaginosis. The SPA outcome provides a binding agreement from the FDA that the phase 3 clinical study design, endpoints, statistical analyses and other aspects of the planned studies adequately address objectives in support of a US regulatory submission for approval of the product. The first step for the FDA is to verify that the gel is safe for vaginal application. Starpharma will commence two pivotal phase 3 clinical trials of VivaGel for the prevention of recurrent BV at sites in North America, Europe and Asia. Approximately 600 women will be recruited into each trial.
No current plans have been made to create a stand alone product, sold in gel, but the company is not ruling that out for the future, Fairley noted. Currently marketing and selling approval has been granted in Japan, the world's second largest condom market.
An unrelated company to Starpharma called Optimally Holding Co., Ltd. is marketing a product called "VIVAgel." But this product with a seemingly similar name does not contain the active ingredient in the VivaGel trials and product and is a fraudulent site.
- In Wake Of Murder, International Day to End Violence Against Sex Workers
- Chinese Gay Dating App Grows To 15 Million Users
- Scores Of Russian Gays Seeking Asylum In US
- Indian LGBTs March For Their Rights
- Marriott Earns Perfect Ranking On Corporate Equality Index
- Global Survey Says Acceptance Of Homosexuality Increasing
- Sweet Dreams
- Banquet Hall/Catering
- Andiamo Italia Banquet Center
- Community Centers
- Jim Toy Community Center
- Families and Parents
- PFLAG - Holland/Lakeshore
- Lewis Jewelers
- Kalamazoo Institute of Arts
- Political Organizations
- Pro-Choice Advocates
- Social/Community Organizations
- Black & White Men Together Detroit
- Berman Center for the Performing Arts
- Youth Services
- Carl Rippberger Youth Services Program
Enter contests to win great prizes like CDs, DVDs, concert tickets and more
- Q&A: Kathy Griffin Reveals Death-Related Talk With Joan Rivers, Plans To Get Fired From 'Fashion Police' & Cher's Health
- Missing Person Found In Metro Detroit
- EXCLUSIVE! Gwen Stefani On Why She Paints Her Boys' Nails, Meeting Gays 'Late In Life' & Her (Lack Of) Girl Crushes
- Q&A: Harvey Fierstein Opens Up On The Success Of 'Kinky Boots,' His 'Legendary Disaster' & 'Insulting' Double Standards
- Marriage Of 300 Same-Sex Couples Ruled Valid In Michigan
Sign up to receive our weekly newsletters today!
A study published in the journal The Lancet HIV reports that there is a significant disparity in HIV prevalence between black and white men who have sex with men. The study was published on Nov. 18 and found a startling 32 percent prevalence rate for black men who have sex with men, compared with only eight percent for white men who have sex with men.View More World AIDS Day
This Week's Issue
Download or view this week's print issue today!
Sign up to receive our weekly newsletters today!